141 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27997164	18	Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting thea	Universit£
27774126	95	Exploring	University of California San Francisco
26753814	7	Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dualaVß3 anda5ß1 integrin ligands.	University of Florence
24949551	22	Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.	Philipps-Universit£T Marburg
24973662	8	Targeting integrinsavß3 anda5ß1 with newß-lactam derivatives.	University of Bologna
24654918	19	Pharmacophoric modifications lead to superpotentavß3 integrin ligands with suppresseda5ß1 activity.	Technische Universit£T M£Nchen
24412498	15	Synthesis and assay of retro-a4ß1 integrin-targeting motifs.	University of Bologna
24095096	3	Synthesis and in vitro evaluation of a novel radioligand foravß3 integrin receptor imaging: [18F]FPPA-c(RGDfK).	University Hospital of Geneva
23811088	26	Modulation ofavß3- anda5ß1-integrin-mediated adhesion by dehydro-ß-amino acids containing peptidomimetics.	University of Bologna
23376251	32	Towards dual antithrombotic compounds - balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism.	University of Ljubljana
23362923	59	Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.	Technische Universit£T M£Nchen
20088512	4	One step radiosynthesis of 6-[(18)F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester ([(18)F]F-Py-TFP): a new prosthetic group for efficient labeling of biomolecules with fluorine-18.	University of Troms£
19959360	50	SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.	Jerini
19910191	46	Discovery of orally available integrin alpha5beta1 antagonists.	Jerini
21601452	2	Tetrazine-trans-cyclooctene ligation for the rapid construction of integrinavß3 targeted PET tracer based on a cyclic RGD peptide.	University of Delaware
21349709	6	Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging.	Washington University
20888763	8	Synthesis and evaluation of bivalent, peptidomimetic antagonists of theavß3 integrins.	The Methodist Hospital Research Institute
17289386	10	Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics.	Universit£
16982193	26	Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.	Chinese Academy of Medical Sciences and Peking Union Medical College
16854058	8	Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents.	University of Southern California
16722662	2	Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.	University of Naples Federico Ii
16570923	8	Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors.	Washington University
15715477	3	Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.	University of Southern California
15369386	11	Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.	Merck Research Laboratories
15863341	33	Non-peptidic alpha(v)beta3 antagonists containing indol-1-yl propionic acids.	Johnson & Johnson Pharmaceutical Research and Development
15357963	16	Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone.	Merck Research Laboratories
14521404	10	Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design.	Technische Universit£T M£Nchen
11020288	13	Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist.	Merck Research Laboratories
8893849	10	Synthesis and solution conformation of cyclo[RGDRGD]: a cyclic peptide with selectivity for the alpha V beta 3 receptor.	Texas A&M University
7650686	3	Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.	Merck Research Laboratories
15013021	10	Non-peptide alpha v beta 3 antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivatives.	Merck Research Laboratories
12643914	40	Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas.	Bayer
14643310	6	Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint.	Merck Research Laboratories
12419389	13	Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements.	Merck Research Laboratories
11755355	32	Biphenyls as potent vitronectin receptor antagonists.	Bayer
12161158	11	Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics.	Merck Research Laboratories
11992781	31	Synthesis of highly potent and selective hetaryl ureas as integrin alpha(V)beta3-receptor antagonists.	Basf
11738567	16	Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements.	Merck Research Laboratories
11738566	20	Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.	Merck Research Laboratories
9873697	15	Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model.	Smithkline Beecham Pharmaceuticals
23140358	28	Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrinaVß3.	Universit£
22959246	24	Camptothecins in tumor homing via an RGD sequence mimetic.	Sigma-Tau Industrie Farmaceutiche Riunite
22871580	6	Near-infrared fluorescent divalent RGD ligand for integrinavß3-targeted optical imaging.	Washington University
22621422	2	¹²5I-radiolabeled morpholine-containing arginine-glycine-aspartate (RGD) ligand ofavß3 integrin as a molecular imaging probe for angiogenesis.	University of Florence
22575869	61	Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 1.	Astrazeneca
22572578	124	Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 2.	Astrazeneca
20055426	30	Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.	Universita Degli Studi Di Bologna
19860432	42	alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers.	Universite Catholique De Louvain
18343671	8	Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands.	Department of Organic Chemistry Ugo Schiff University of Firenze Via Della Lastruccia 13
18303826	48	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.	Universit£
18068982	20	Design and synthesis of novel potent and selective integrin alphanubeta3 antagonists--novel synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates.	Basf
17184884	16	Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.	Johnson & Johnson Pharmaceutical Research and Development
16302808	28	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.	Universit£
15357991	20	Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.	3-Dimensional Pharmaceuticals
12139455	78	Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.	Genentech
9191954	9	Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.	Merck Research Laboratories
10673106	28	RGD mimetics containing a central hydantoin scaffold: alpkha(v)beta3 vs alpha(IIb)beta3 selectivity requirements.	Hoechst Marion Roussel
22365562	154	Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold.	University of Ljubljana
21344906	54	Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.	The University of Tokyo
20951038	3	Small molecule inhibitors of hantavirus infection.	University of New Mexico School of Medicine
20809642	28	Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.	University of Florence
20218623	68	Emerging targets in osteoporosis disease modification.	Amgen
19942441	47	Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation.	Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
17973471	24	Multiple N-methylation by a designed approach enhances receptor selectivity.	Technische UniversitäT MüNchen
17910915	19	Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.	Bayer Healthcare
17869121	32	Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.	Università
17616113	63	Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.	Jerini
17399986	114	R-isomers of Arg-Gly-Asp (RGD) mimics as potent alphavbeta3 inhibitors.	Pfizer
17387018	74	Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.	Pfizer
16621534	87	Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.	Pfizer
16509596	29	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.	Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
16303301	44	Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.	Pfizer
16298127	80	Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.	Pfizer
15974570	30	Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists.	Università
15745815	7	Nonpeptide alpha(v)beta3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics.	Merck Research Laboratories
15715463	16	Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.	Johnson and Johnson Pharmaceutical Research & Development
15501072	58	1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.	Johnson & Johnson Pharmaceutical Research & Development
15380233	46	Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.	Johnson & Johnson Pharmaceutical Research and Development
15125957	23	N-Aryl-gamma-lactams as integrin alphavbeta3 antagonists.	Amgen
15109653	30	Discovery of a potent and selective alpha v beta 3 integrin antagonist with strong inhibitory activity against neointima formation in rat balloon injury model.	Dainippon Pharmaceutical
15056002	112	Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.	Millennium Pharmaceuticals
15006384	179	Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists.	Pfizer
14741263	67	Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3.	Nerviano
14640540	18	Molecular model of the alpha(IIb)beta(3) integrin.	Merck Research Laboratories
14561098	8	Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.	Merck Research Laboratories
12729670	49	Non-peptide alphavbeta3 antagonists. Part 6: design and synthesis of alphavbeta3 antagonists containing a pyridone or pyrazinone central scaffold.	Merck Research Laboratories
12668017	17	Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.	Glaxosmithkline
12565960	33	Thiophene-based vitronectin receptor antagonists.	Shire Biochem
12565923	6	Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors.	Leiden University
12482416	52	Highly potent and selective alphaVbeta3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones.	Basf
12477347	16	Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin.	Merck Research Laboratories
12392735	30	Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.	Institut De Recherches Servier
11855984	102	Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.	Merck
11814816	30	Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(V)beta(3) antagonists.	Knoll
11714601	9	Discovery and evaluation of piperidinyl carboxylic acid derivatives as potent alpha(4)beta(1) integrin antagonists.	Bayer
32094009	36	Novel cilengitide-based cyclic RGD peptides as ?v?	Division of Organic Chemistry Csir-National Chemical Laboratory (Ncl)
11454469	95	alpha(v)beta(3) Antagonists based on a central thiophene scaffold.	Aventis Pharma Deutschland
11392539	34	Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes.	Cor Therapeutics
11384239	82	Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists.	Technische UniversitäT MüNchen
11327582	23	2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.	Taisho Pharmaceutical
32571015	2	Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin ?v?3 Receptors in the Treatment of Neuroblastoma.	Albany College of Pharmacy and Health Sciences
31999923	16	Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.	Pliant Therapeutics
10853677	34	Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.	Celltech Chiroscience
30732943	8	Design and synthesis of novel dual-cyclic RGD peptides for ?	Nanchang University
30657681	262	Selective Targeting of Integrin ?v?8 by a Highly Active Cyclic Peptide.	Technische Universit£T M£Nchen
10633037	88	Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3).	Dupont Pharmaceuticals
10633036	79	Isoxazolines as potent antagonists of the integrin alpha(v)beta(3).	Dupont Pharmaceuticals
10633035	20	Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.	Smithkline Beecham Pharmaceuticals
10447947	14	N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.	Technische UniversitäT MüNchen
10406646	15	Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.	Smithkline Beecham Pharmaceuticals
10406645	36	Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics.	Smithkline Beecham Pharmaceuticals
10230615	60	Rapid synthesis of RGD mimetics with isoxazoline scaffolds on solid phase: identification of alphavbeta3 antagonists lead compounds.	Dupont Pharmaceuticals
10197962	13	Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.	Dupont Pharmaceuticals
31381331	70	Profile of a Highly Selective Quaternized Pyrrolidine Betaine ?	Glaxosmithkline Medicines Research Centre
31306009	64	Cyclization of RGD Peptides by Suzuki-Miyaura Cross-Coupling.	Bielefeld University
9873696	80	Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists.	Smithkline Beecham Pharmaceuticals
31497959	48	Discovery of an Orally Bioavailable Pan ?v Integrin Inhibitor for Idiopathic Pulmonary Fibrosis.	Glaxosmithkline Medicines Research Centre
9435900	89	Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.	Cor Therapeutics
9288166	74	Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.	Eli Lilly
9240343	28	Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.	Smithkline Beecham Pharmaceuticals
31670514	45	Could Dissecting the Molecular Framework of ?-Lactam Integrin Ligands Enhance Selectivity?	University of Bologna
26818999	2	Insight to the binding mode of triazole RGD-peptidomimetics to integrin-rich cancer cells by NMR and molecular modeling.	University of Milano
26101577	15	Dehydro-?-proline Containing ?4?1 Integrin Antagonists: Stereochemical Recognition in Ligand-Receptor Interplay.	University of Bologna
25721024	4	In silico studies, synthesis and binding evaluation of substituted 2-pyrrolidinones as peptidomimetics of RGD tripeptide sequence.	Universit£
24568695	76	Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.	University of Bradford
25408832	152	Structure Activity Relationships of ?v Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents.	University of Nottingham
8057299	66	Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.	Merck Research Laboratories
17027271	13	Natural inhibitors targeting osteoclast-mediated bone resorption.	Chinese Academy of Sciences
30215258	228	Discovery of ( S)-3-(3-(3,5-Dimethyl-1 H-pyrazol-1-yl)phenyl)-4-(( R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic ?	University of Strathclyde
29883545	6	Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to ?	Irccs Ospedale San Raffaele
29775303	60	Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme.	Universit£
29348803	5	Synthesis of a Chloroalkene Dipeptide Isostere-Containing Peptidomimetic and Its Biological Application.	Tokyo Medical and Dental University
1469694	22	Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.	Merck Research Laboratories
28351594	24	New potent and selective?v?	Jiangnan University